300119.SHE Tianjin Ringpu Bio Tech
- Market cap
- CNY 7.83B
- P/E
- 21.9x
- P/B
- 1.58x
- ROE
- 8.3%
- Dividend yield
- 2.14%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300119.SHE undervalued?
Graham number300119.SHE trades 23.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tianjin Ringpu Bio Tech fundamental analysis
No fundamental analysis for Tianjin Ringpu Bio Tech yet.
Tianjin Ringpu Bio Tech stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tianjin Ringpu Bio Tech
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, pharmaceutical preparation, functional additives, and veterinary biological products. The company provides vaccines, chemical drugs, traditional Chinese medicines; feed additives, including pigs, chickens, waterfowl, cattle, sheep and pet medicines, and vaccines; and poultry, waterfowl, livestock, rumination, pets, washing and disinfection, active…
Full company profileTianjin Ringpu Bio Tech financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tianjin Ringpu Bio Tech annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 970M | 1.05B | 1.19B | 1.47B | 2.00B | 2.01B | 2.08B | 2.71B | 3.07B | 3.40B | 3.56B |
| Gross Profit | 556M | 555M | 596M | 766M | 1.08B | 1.04B | 1.01B | 1.18B | 1.25B | 1.40B | 1.42B |
| Operating Income | 150M | 142M | 162M | 263M | 513M | 499M | 417M | 570M | 373M | 442M | 533M |
| EBITDA | 266M | 251M | 271M | 376M | 634M | 596M | 550M | 737M | 594M | 729M | 534M |
| Net Income | 133M | 105M | 119M | 194M | 398M | 413M | 347M | 454M | 301M | 401M | 398M |
| EPS | 0.34 | 0.26 | 0.29 | 0.49 | 1.01 | 1.03 | 0.75 | 0.98 | 0.65 | 0.86 | 0.86 |
| Balance Sheet | |||||||||||
| Total Assets | 2.73B | 2.92B | 3.00B | 3.56B | 3.90B | 5.69B | 6.11B | 6.60B | 7.97B | 7.66B | 8.24B |
| Total Liabilities | 628M | 748M | 744M | 1.21B | 1.16B | 1.37B | 1.61B | 1.79B | 2.96B | 2.47B | 2.93B |
| Shareholders' Equity | 1.90B | 1.95B | 2.01B | 2.12B | 2.46B | 4.03B | 4.22B | 4.50B | 4.47B | 4.70B | 4.79B |
| Cash & Short-term Investments | 295M | 398M | 288M | 782M | 694M | 1.89B | 1.89B | 1.62B | 1.94B | 651M | 414M |
| Total Debt | 255M | 388M | 354M | 638M | 561M | 739M | 878M | 872M | 1.32B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 208M | 108M | 175M | 384M | 388M | 383M | 389M | 378M | 736M | 298M | - |
| Capital Expenditure | 128M | 109M | 112M | 230M | 259M | 306M | 372M | 244M | 185M | 176M | 272M |
| Free Cash Flow | 79.5M | -1.30M | 62.4M | 154M | 129M | 76.8M | 17.1M | 134M | 550M | 121M | 232M |
| Ratios | |||||||||||
| ROE | 7.0% | 5.4% | 5.9% | 9.2% | 16.2% | 10.2% | 8.2% | 10.1% | 6.7% | 8.5% | 8.3% |
| ROA | 4.9% | 3.6% | 4.0% | 5.5% | 10.2% | 7.3% | 5.7% | 6.9% | 3.8% | 5.2% | 4.8% |
| Net Profit Margin | 13.7% | 10.0% | 10.0% | 13.3% | 19.9% | 20.6% | 16.6% | 16.7% | 9.8% | 11.8% | 11.2% |
| Debt to Equity | 0.13x | 0.20x | 0.18x | 0.30x | 0.23x | 0.18x | 0.21x | 0.19x | 0.30x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tianjin Ringpu Bio Tech dividends
- Dividend yield
- 2.14%
- Forward dividend
- 0.40 CNY
- Payout ratio
- 41.8%
- Ex-dividend date
- May 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 167M | 0.36 | 41.8% |
| 2024 | CNY 216M | 0.47 | 71.8% |
| 2023 | CNY 163M | 0.35 | 35.9% |
| 2022 | CNY 164M | 0.35 | 47.2% |
| 2021 | CNY 160M | 0.40 | 38.8% |
| 2020 | CNY 100M | 0.25 | 25.1% |
| 2019 | CNY 60.7M | 0.15 | 31.2% |
| 2018 | CNY 80.3M | 0.20 | 67.5% |
| 2017 | CNY 75.1M | 0.19 | 71.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 19.93579:10 on Apr 22, 2014.
Who owns Tianjin Ringpu Bio Tech
- Insiders 50.94%
- Institutions 4.48%
- Public & others 44.58%
- Shares outstanding 465M
- Free float 233M
Tianjin Ringpu Bio Tech company profile
- Company name
- Tianjin Ringpu Bio Tech
- Ticker
- 300119.SHE
- ISIN
- CNE100000TV1
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Sep 17, 2010
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,803
- Fiscal year end
- December
- Address
- No. 1, East 9th Road, Tianjin, China, 300308
- Phone
- 86 22 8895 8118
- Website
- ringpu.com
About Tianjin Ringpu Bio Tech
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, pharmaceutical preparation, functional additives, and veterinary biological products. The company provides vaccines, chemical drugs, traditional Chinese medicines; feed additives, including pigs, chickens, waterfowl, cattle, sheep and pet medicines, and vaccines; and poultry, waterfowl, livestock, rumination, pets, washing and disinfection, active pharmaceutical ingredients product series. It also offers diagnosis and treatment services, such as epidemic diagnosis and testing, animal drug evaluation, and veterinary socialization. The company was founded in 1998 and is headquartered in Tianjin, China.
Tianjin Ringpu Bio Tech management
6- Mr. Lei XuGM & Director · born 1973
- Ms. Gaibian LiFinancial Manager · born 1975
- Ms. Ailing LiuDeputy GM & Director · born 1975
- Mr. Xiutong ZhuNon-Independent Director & Deputy GM · born 1981
- Mr. Gang XieBoard Secretary · born 1985
- Cai Xia WangHead of Accounting Department